Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Some of these are mentioned below. How much Dupixent costs is based on several factors. These can include your prescribed treatment regimen, your insurance plan, the pharmacy you use, and your ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Dupixent remains a top growth driver ... Due to legal, regulatory, operational costs, and more emphasis on R&D investments, Sanofi's FCF will likely be reduced in the near term.

DUPIXENT sales contribute to Regeneron's revenue ... US annually and perhaps 5-10% fall into the high risk category. The cost for a supply of 7mL for IV infusion is $11,178. While this is a ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...